Agios Pharmaceuticals Inc (NASDAQ: AGIO) started the day on Thursday, with a price decrease of -8.23% at $35.81, before settling in for the price of $39.02 at the close. Taking a more long-term approach, AGIO posted a 52-week range of $20.96-$62.58.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 2.66%. Meanwhile, its Annual Earning per share during the time was -0.98%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 280.77%. This publicly-traded company’s shares outstanding now amounts to $57.02 million, simultaneously with a float of $55.14 million. The organization now has a market capitalization sitting at $2.04 billion. At the time of writing, stock’s 50-day Moving Average stood at $49.60, while the 200-day Moving Average is $42.14.
Agios Pharmaceuticals Inc (AGIO) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Agios Pharmaceuticals Inc’s current insider ownership accounts for 3.32%, in contrast to 104.72% institutional ownership. According to the most recent insider trade that took place on Dec 11 ’24, this organization’s Director sold 200 shares at the rate of 46.28, making the entire transaction reach 9,256 in total value, affecting insider ownership by 15,483. Preceding that transaction, on Nov 08 ’24, Company’s Principal Accounting Officer sold 772 for 56.09, making the whole transaction’s value amount to 43,301. This particular insider is now the holder of 813 in total.
Agios Pharmaceuticals Inc (AGIO) Earnings and Revenue Records
Agios Pharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 280.77% and is forecasted to reach -6.13 in the upcoming year.
Agios Pharmaceuticals Inc (NASDAQ: AGIO) Trading Performance Indicators
Let’s observe the current performance indicators for Agios Pharmaceuticals Inc (AGIO). It’s Quick Ratio in the last reported quarter now stands at 8.77. The Stock has managed to achieve an average true range (ATR) of 3.81. Alongside those numbers, its PE Ratio stands at $3.15, and its Beta score is 0.85. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 62.13.
In the same vein, AGIO’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 11.37, a figure that is expected to reach -1.69 in the next quarter, and analysts are predicting that it will be -6.13 at the market close of one year from today.
Technical Analysis of Agios Pharmaceuticals Inc (AGIO)
If we take a close look at the recent performances of Agios Pharmaceuticals Inc (NASDAQ: AGIO), its last 5-days Average volume was 1.18 million that shows progress from its year to date volume of 0.72 million. During the previous 9 days, stock’s Stochastic %D was recorded 9.16% While, its Average True Range was 4.15.
Raw Stochastic average of Agios Pharmaceuticals Inc (AGIO) in the period of the previous 100 days is set at 1.14%, which indicates a major fall in contrast to 1.15% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 121.27% that was higher than 64.83% volatility it exhibited in the past 100-days period.
